PPARG and pulmonary fibrosis: In vivo, various PPARγ agonists, including troglitazone and rosiglitazone, were effective in inhibiting BLM-induced pulmonary fibrosis, and PPARγ agonists were also effective in inhibiting paraquat-induced pulmonary fibrosis21–25.